STAT+: Pharmalittle: Califf sails through hearing for top FDA job; J.P. Morgan goes virtual after big biotechs pull out
Hello, everyone, and how are you today? We are doing just fine, thank you, since…
Category: STAT+
STAT+: Biotech investor Eli Casdin on biotech’s bad December
Biotech investors are having some not-so-happy holidays. In the last few months, several major funds…
STAT+: Moderna, Amgen among biotech heavyweights pulling out of JPM conference over Covid concerns
Some of the biggest names in biotechnology, including Amgen, Moderna, and Sarepta Therapeutics, have pulled…
STAT+: Pharmalittle: Pfizer Covid pill retains 89% efficacy in full study; Senate committee holds hearing on FDA commissioner
Rise and shine, folks, another busy day is on the way. We can tell, thanks…
STAT+: STAT+ Conversation: The Whitest Medical Specialty
Editor’s note: A livestream of the conversation will be embedded below at 2 p.m. ET….
.jpg)
STAT+: Oregon wants to get out of covering drugs like Aduhelm in Medicaid
WASHINGTON — Oregon is gearing up to ask the Biden administration if its Medicaid program…
STAT+: Hospitals just dodged a bullet in Democrats’ major spending package. Can they sidestep a bigger one?
WASHINGTON — Hospitals and their lobbyists in Washington just wriggled their way out of a…
STAT+: Feeling remote: Coalition of pharma regulators look to complement on-site inspections beyond Covid
Nearly two years after the Covid-19 pandemic prompted remote inspections of pharmaceutical production plants, an…
STAT+: Pharmalittle: Pfizer to pay $6.7 billion for Arena and a bowel disease drug; ASH brings flood of data readouts
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: More potent version of Global Blood sickle-cell drug improves hemoglobin response in small study
Global Blood Therapeutics said Monday that an experimental treatment for sickle cell disease nearly doubled…
STAT+: In a do-over study, Bellus Health cough treatment shows positive results
Results released Monday from a Phase 2 study of a chronic cough treatment being developed…
STAT+: J&J’s new CAR-T therapy shows long-term success, data show
By the time patients with multiple myeloma have gone through four or five different therapies,…
STAT+: Mutations tied to blood cancers and other diseases may surprisingly protect against Alzheimer’s
ATLANTA — When key mutations strike bone marrow stem cells, known as hematopoietic stem cells,…
.jpg)
STAT+: Roche two-armed antibody posts strong tumor responses in lymphoma study, rivaling CAR-T therapy
An off-the-shelf bispecific antibody developed by Roche induced high and durable response rates in patients…
STAT+: Patients with rare blood disorder benefit from Bluebird gene therapy while denied access in Europe
People with severe beta-thalassemia who live in Europe have been denied access to Bluebird Bio’s…
STAT+: Gilead, Bristol jaw over the superiority of rival CAR-T treatments for blood cancer
Competing, bespoke CAR-T cell therapies from Gilead Sciences and Bristol Myers Squibb have each demonstrated…
STAT+: Generic drug makers win a court round as judge temporarily blocks California pay-to-delay law
In a victory for generic drug makers, a federal court judge temporarily blocked a controversial California…
STAT+: Pharmalittle: Fauci unconvinced Omicron-specific vaccines are needed; J&J rebuffed warnings about a diabetes drug
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: Maintaining trust in science is crucial to public health. Here’s how the biopharma industry can help
Against declining trust in traditional news sources and institutions that provide data and information, the…
STAT+: Hospital, physician lobbies sue Biden administration over surprise billing regulation
WASHINGTON — The nation’s largest hospital and physician lobbying groups are suing the Biden administration…
STAT+: Pharmalittle: Biotech VC firms charge their startups ‘consulting’ fees; FDA authorizes preventive Covid antibody cocktail
Hello, everyone, and how are you today? We are doing just fine, thank you. After…
STAT+: At biotech venture capital firms, collecting ‘consulting fees’ from startups has become widespread
Some of the biggest names in biotech venture capital have charged their startups millions of…
STAT+: AbbVie unit to pay $200 million to resolve closely watched opioid lawsuit in New York
Allergan, which is a unit of AbbVie (ABBV) agreed to pay up to $200 million…
STAT+: In the blood of marathoning mice, scientists find clues to how exercise benefits the brain
If you give a mouse a wheel, it will run, and run, and run: between…
STAT+: Pharmalittle: Biogen prepares for large layoffs; Pfizer Covid booster neutralized Omicron but variant may elude two doses
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Martin Shkreli’s former company pays $40 million for blocking competition for a life-saving drug
Six years after a national scandal erupted, a group of federal and state authorities have…
STAT+: Centene agrees to pay $28 million to resolve another state probe into its PBM business
Centene (CNC), one of the largest health insurers in the U.S., agreed to pay nearly…
STAT+: ‘A multi-decade journey’: Chan Zuckerberg Initiative invests another $3.4 billion to advance scientific tools
As Mark Zuckerberg aims to build his social network empire into the foundation for a…
STAT+: Pharmalittle: Glaxo and Vir antibody remains effective against Omicron; Biden talks up drug-pricing reform
Top of the morning to you, and a fine one it is. Sunny skies and…
STAT+: STAT+ Conversation: The ‘Shroom Boom’
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET. Every…
STAT+: Carbon Health launches a program for continuous glucose monitoring to curb diabetes risk
In April, endocrinologist Calvin Wu described how his company, Steady Health, was making use of…
STAT+: Major telehealth players unite ahead of tough lobbying battle
WASHINGTON — Major players in the telehealth space have united to create a supergroup of…
STAT+: Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s
Flagship Pioneering is gearing up to launch a new company that seems to be developing…
STAT+: Targeting prices for accelerated approval drugs may have limited impact on overall drug spending
As U.S. regulators approve more medicines under the accelerated approval pathway, Medicare and Medicaid continue…
STAT+: Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease
An experimental drug being developed by Acadia Pharmaceuticals improved the symptoms of women and girls…
STAT+: As Biden touts his effort to cap insulin prices, advocates push for an even more ambitious reform
WASHINGTON — President Biden promised Monday that Democrats’ signature drug pricing plan will mean no…
STAT+: Pharmalittle: Covid-19 pills may take longer to reach poor countries; J&J Covid booster may be as beneficial as a third Pfizer shot
Hello, everyone, and welcome to another working week. We hope the weekend respite was relaxing…
STAT+: The pandemic forced an experiment in delivering intensive mental health care from home. Will the approach stick?
When the pandemic lockdowns slammed society’s doors closed in March 2020, the leaders at McLean…
STAT+: Stoke Therapeutics drug, targeting genetic cause of childhood epilepsy, reduces seizure activity
An experimental drug from Stoke Therapeutics reduced the frequency of convulsive seizures in children with…
STAT+: Pharmalittle: FDA plans rapid review of Omicron vaccines and drugs; Califf would keep Woodcock at FDA
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Former Immunomedics executives are charged with insider trading
Two former executives at Immuomedics were charged with insider trading by U.S. authorities in connection…
STAT+: Hospitals and doctors fail to stop end-of-year Medicare cuts, for now
WASHINGTON — Hospitals and physicians lost a lobbying battle to stave off Medicare cuts of…
STAT+: Pharmalittle: Glaxo and Vir drug appears to work against Omicron; employees sue Bristol Myers over vaccine mandate
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Artificial intelligence is making a pitch to transform radiology. Will it pay off for hospitals?
For radiologists working today, the specter of artificial intelligence is inescapable. In the past year,…
STAT+: Liquid biopsies could help screen for countless cancers. But who should get them?
By the time cancer is discovered, it’s often too late to change its course. Close…
STAT+: Amgen joins a growing list of drug makers cutting discounts to safety-net hospitals
Amid a closely watched legal battle, Amgen (AMGN) has joined the growing ranks of major…
STAT+: Pharmalittle: Merck Covid pill squeaks past FDA panel; analysis explores whether insurers give ‘fair access’ to drugs
Top of the morning to you, and a fine one it is. A shiny sun…
STAT+: In a medical first, Vertex drug successfully targets the underlying cause of a genetic kidney disease
An experimental pill from Vertex Pharmaceuticals reduced levels of a damaging urine protein by nearly…
STAT+: Socially responsible investor coalitions push greater access to medicines in shareholder proposals
Amid controversy over equitable distribution of Covid-19 vaccines, a large coalition of socially minded investor…
STAT+: Pharmalittle: Moderna CEO cautions Covid shots will be less effective against Omicron; Pfizer predicts new vaccine for the variant in 100 days
Rise and shine, everyone, another busy day is on the way. We can tell because…